Stone Run Capital’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
Sell
-21,767
Closed -$2.44M 67
2016
Q3
$2.44M Sell
21,767
-50
-0.2% -$5.76K 1.52% 32
2016
Q2
$2.7M Buy
21,817
+2,575
+13% +$311K 1.76% 29
2016
Q1
$2.16M Sell
19,242
-1,083
-5% -$113K 1.39% 35
2015
Q4
$2.21M Buy
20,325
+1,300
+7% +$149K 1.54% 31
2015
Q3
$1.9M Buy
19,025
+2,400
+14% +$261K 1.51% 28
2015
Q2
$1.9M Sell
16,625
-50
-0.3% -$6.06K 1.24% 36
2015
Q1
$1.74M Buy
16,675
+10,275
+161% +$1.09M 1.12% 36
2014
Q4
$937K Hold
6,400
0.64% 52
2014
Q3
$937K Hold
6,400
0.66% 51
2014
Q2
$1.07M Hold
6,400
0.7% 50
2014
Q1
$1.27M Sell
6,400
-150
-2% -$28.3K 0.92% 43
2013
Q4
$1.25M Hold
6,550
0.88% 44
2013
Q3
$1.11M Hold
6,550
0.9% 45
2013
Q2
$993K Buy
+6,550
New +$928K 0.96% 41

Other funds holding CLB

Stone Run Capital's CLB Position: Q4 2016 in Review

Stone Run Capital sold out of Core Laboratories (CLB) in Q4 2016, closing a stake of 21,767 shares — an estimated $2.44M sold.

Stone Run Capital first reported a position in CLB in Q2 2013 and held it in 14 quarters. The position peaked at $2.7M in Q2 2016. 373 funds tracked by Wall St. Rank hold CLB as of Q4 2016.

  • Stone Run Capital reported no remaining Core Laboratories position as of Q4 2016 after selling out during the quarter.
  • Stone Run Capital sold 21,767 Core Laboratories shares in Q4 2016, an estimated $2.44M.
  • Stone Run Capital first reported a position in Core Laboratories in Q2 2013 and held it in 14 quarters.
  • Stone Run Capital's Core Laboratories position peaked at $2.7M in Q2 2016.
  • 373 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2016.

Based on Stone Run Capital's 13F filing for Q4 2016, filed 13 Feb 2017.